High Survival Rates With Seed Implants in Early Prostate Ca

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 2
Volume 16
Issue 2

More than 90% of prostate cancer patients who receive appropriate radiation dose levels with permanent radiation seed implants are cured 8 years after diagnosis

• FAIRFAX, Virginia—More than 90% of prostate cancer patients who receive appropriate radiation dose levels with permanent radiation seed implants are cured 8 years after diagnosis, according to a study in the February 1, 2007, issue of the International Journal of Radiation Oncology*Biology*Physics (67:327-333, 2007). The study evaluated results in nearly 2,700 men with early-stage prostate cancer treated at 11 US institutions. Ultrasound-guided techniques were used to place the seeds. Patients received the seed implants as the sole treatment for prostate cancer.

"This study is exciting because it shows that brachytherapy alone can be effective at curing early-stage prostate cancer," said Michael J. Zelefsky, MD, lead author and chief of brachytherapy services at Memorial Sloan-Kettering Cancer Center. "These results also confirm other findings that the quality of the seed implant is a critical ingredient for achieving a better outcome."

Related Videos
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Financial constraints and a lack of education among some patients and providers must be addressed to improve the real-world use of certain prostate cancer therapies, says Neeraj Agarwal, MD.
Novel anti-PSMA monoclonal antibody rosopatamab is capable of carrying a bigger payload of radiation particles, which may potentially reduce doses for patients with prostate cancer, says Neeraj Agarwal, MD.
Related Content